Table 2 |
||||||||||
|
Evaluation of therapeutic effect of milk antibody treatment in 18 patients in test group. |
||||||||||
|
Patient ID |
Eval Point1) |
ACR2) Criteria |
DAS28-ESR |
Remarks of improvements |
DRB1- Allele |
|||||
|
|
||||||||||
|
Pre |
Post |
Δ |
EULAR3) |
GI4) |
General condition5) |
|||||
|
|
||||||||||
|
Responders |
||||||||||
|
3709 |
8 |
20 |
6.01 |
3.47 |
2.54 |
Moderate |
C (+) |
Fatigue, Anemia, Weight loss |
0101 |
0405 |
|
3188 |
8 |
20 |
6.31 |
4.82 |
1.49 |
Moderate |
C (+) |
ADL |
0405 |
0404 |
|
4119 |
6 |
50 |
4.61 |
3.39 |
1.22 |
Moderate |
(/) |
Range of motion |
0901 |
1406 |
|
198 |
6 |
<20 |
8.02 |
7.13 |
0.89 |
No |
C (+) |
Fatigue, Anemia |
0803 |
1401 |
|
5284 |
5 |
<20 |
4.32 |
3.07 |
1.25 |
Good |
C (+) |
Unhealthy feeling |
0410 |
1502 |
|
10572 |
3 |
<20 |
6.12 |
6.08 |
0.04 |
No |
C (+) |
Appetite, Sleep |
1302 |
1406 |
|
1316 |
3 |
<20 |
4.34 |
4.21 |
0.13 |
No |
C (+) |
Fatigue |
ND |
ND |
|
3240 |
3 |
<20 |
5.29 |
4.63 |
0.66 |
Moderate |
D (+) |
Unhealthy feeling |
0405 |
1202 |
|
|
||||||||||
|
Ave |
5.3 ± 2.1 |
5.63 ± 1.26 |
4.66 ± 1.43 |
0.97 ± 0.87 |
(7/7) |
|||||
|
Pre vs. Post |
P < 0.01 |
P < 0.01 |
||||||||
|
|
||||||||||
|
Partial responders |
||||||||||
|
169 |
2 |
<20 |
5.26 |
6.22 |
-0.96 |
No |
(/) |
Fatigue, Intra-articular effusion |
0901 |
- |
|
511 |
1 |
<20 |
8.15 |
7.85 |
0.30 |
No |
D (+) |
Range of motion |
0405 |
1101 |
|
|
||||||||||
|
Ave |
1.5 ± 0.7 |
6.75 ± 2.10 |
7.04 ± 1.15 |
-0.33 ± 0.89 |
(1/1) |
|||||
|
|
||||||||||
|
Non-Responders |
||||||||||
|
9291 |
2 |
<20 |
4.70 |
5.04 |
-0.34 |
No |
C (+) |
- |
0803 |
1501 |
|
3007 |
1 |
<20 |
4.44 |
5.85 |
-1.41 |
No |
(/) |
- |
1101 |
1502 |
|
2264 |
1 |
<20 |
8.00 |
7.86 |
0.14 |
No |
C (+) |
- |
0405 |
- |
|
721 |
1 |
<20 |
6.33 |
6.29 |
-0.04 |
No |
C (+) |
- |
0405 |
1501 |
|
7785 |
0 |
<20 |
6.22 |
7.58 |
-1.36 |
No |
C (-) |
Edema at lower thigh |
0901 |
1501 |
|
2110 |
0 |
<20 |
ND |
ND |
ND |
ND |
C (-) |
- |
0405 |
1502 |
|
8861 |
0 |
<20 |
4.01 |
5.68 |
-1.67 |
No |
C (-) |
- |
0901 |
1501 |
|
10164 |
0 |
<20 |
4.45 |
4.94 |
-0.49 |
No |
(/) |
- |
0405 |
1501 |
|
|
||||||||||
|
Ave |
0.6 ± 0.7 |
5.45 ± 1.44 |
6.18 ± 1.15 |
-0.73 ± 0.74 |
(3/6) |
|||||
|
Pre vs. Post |
NS |
NS |
||||||||
|
|
||||||||||
|
Responder vs. Non-Responder |
NS |
P < 0.05 |
||||||||
|
|
||||||||||
|
1) Number of categories among 8 categories gained more than 20% improvement. 2) American College of Rheumatology, 3) European League Against Rheumatism response criteria using DAS28-ESR. 4) Gastrointestinal disorder, C: Constipation, D: Diarrhea, (+): improved, (-): not improved, (/): no GI disorder. 5) ADL: activities of daily living. ND: Not determined, NS: Not significant. |
||||||||||
|
Katayama et al. Nutrition Journal 2011 10:2 doi:10.1186/1475-2891-10-2 |
||||||||||
